

### Amendments to the Claims

**1. (Original)** An agent for improving a mental disorder due to cerebral dysfunction, comprising a hepatocyte growth factor.

**2. (Original)** The agent according to claim 1, wherein the mental disorder is a decline in learning function.

**3. (Original)** The agent according to claim 1, wherein the mental disorder is a decline in memory function.

**4. (Original)** The agent according to claim 1, wherein the mental disorder is dementia.

**5. (Original)** An agent for inhibiting vascular hyperpermeability, comprising a hepatocyte growth factor.

**6. (Original)** The agent according to claim 5, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.

**7. (Original)** A composition for improving a mental disorder due to cerebral dysfunction, comprising a hepatocyte growth factor and a pharmaceutically acceptable additive.

**8. (Original)** The composition according to claim 7, wherein the mental disorder is a decline in learning function.

**9. (Original)** The composition according to claim 7, wherein the mental disorder is a decline in memory function.

**10. (Original)** The composition according to claim 7, wherein the mental disorder is dementia.

**11. (Original)** A composition for inhibiting vascular hyperpermeability, comprising a hepatocyte growth factor and a pharmaceutically acceptable additive.

**12. (Original)** The composition according to claim 11, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.

**13. (Original)** A method of improving a mental disorder due to cerebral dysfunction, which comprises administering a hepatocyte growth factor to a mammal.

**14. (Original)** The method according to claim 13, wherein the mental disorder is a decline in learning function.

**15. (Original)** The method according to claim 13, wherein the mental disorder is a decline in memory function.

**16. (Original)** The method according to claim 13, wherein the mental disorder is dementia.

**17. (Original)** A method of inhibiting vascular hyperpermeability, which comprises administering a hepatocyte growth factor to a mammal.

**18. (Original)** The method according to claim 17, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.

**19. (Currently amended)** ~~Use of a hepatocyte growth factor in A method for producing a pharmaceutical preparation for inhibiting a mental disorder due to cerebral dysfunction, which comprises mixing a hepatocyte growth factor with a pharmaceutically acceptable carrier.~~

**20. (Currently amended)** The use method according to claim 19, wherein the mental disorder is a decline in learning function.

**21. (Currently amended)** The use method according to claim 19, wherein the mental disorder is a decline in memory function.

**22. (Currently amended)** The use method according to claim 19, wherein the mental disorder is dementia.

**23. (Currently amended)** Use of a hepatocyte growth factor in A method for producing a pharmaceutical preparation for inhibiting vascular hyperpermeability, which comprises mixing a hepatocyte growth factor with a pharmaceutically acceptable carrier.

**24. (Currently amended)** The use method according to claim 23, wherein the vascular hyperpermeability is cerebrovascular hyperpermeability.